Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
University of Kentucky
OHSU Knight Cancer Institute
Baylor College of Medicine
University of California, Davis
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
West China Hospital
University of Southern California
Roswell Park Cancer Institute
University of Pittsburgh
University of Southern California
Thomas Jefferson University
NuCana plc
Oslo University Hospital
National Cancer Centre, Singapore
Thomas Jefferson University
Thomas Jefferson University
Gustave Roussy, Cancer Campus, Grand Paris
Shandong Cancer Hospital and Institute
The Methodist Hospital Research Institute
UNICANCER
National University Hospital, Singapore
Cancer Research UK
Zhejiang Provincial People's Hospital
Comprehensive Support Project for Oncology Research
Ohio State University Comprehensive Cancer Center
University of California, San Francisco
Sun Yat-sen University
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Providence Health & Services
H. Lee Moffitt Cancer Center and Research Institute
Herlev Hospital
Institut du Cancer de Montpellier - Val d'Aurelle
Centre Leon Berard
Institut Bergonié
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Loma Linda University
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
AHS Cancer Control Alberta
OHSU Knight Cancer Institute
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center